5912-34-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(cyanomethyl)picolinonitrile is used as a key intermediate for the synthesis of various drugs and biologically active compounds. Its ability to participate in multiple chemical reactions makes it a valuable asset in the development of new pharmaceuticals with potential therapeutic applications.
Used in Organic Synthesis:
3-(cyanomethyl)picolinonitrile is utilized as a building block in the synthesis of complex organic molecules. Its reactivity in nucleophilic substitution and palladium-catalyzed cross-coupling reactions allows for the creation of a wide array of organic compounds with diverse applications.
Used in Heterocyclic Compound Preparation:
3-(cyanomethyl)picolinonitrile is employed as a precursor in the preparation of heterocyclic compounds. Its unique structure and reactivity contribute to the formation of heterocyclic rings, which are important in various chemical and pharmaceutical applications.

InChI:InChI=1/C8H5N3/c9-4-3-7-2-1-5-11-8(7)6-10/h1-2,5H,3H2

Upstream product

• 6635-88-7 3-(cyanomethyl)pyridine 1-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 116986-13-1 2-cyano-3-(bromomethyl)pyridine 
• 20970-75-6 2-cyano-3-methylpyridine 
• 6443-85-2 3-pyridinylacetonitrile 
• 79-44-7 N,N-Dimethylcarbamoyl chloride 

Downstream Products

• 5912-35-6 8-bromo-[1,7]naphthyridin-6-ylamine 
• 55716-28-4 8-methoxy-[1,7]naphthyridin-6-ylamine 
• 1201843-32-4 N-(2-chloro-5-(1,7-naphthyridin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 5912-36-7 1,7-naphthyridin-6-amine 
• 524734-50-7 C₂₄H₂₃F₃N₂O₃ 
• 524734-48-3 C₂₃H₂₃FN₂O₂ 
• 524734-51-8 C₂₄H₂₆N₂O₂S 
• 713145-39-2 C₂₁H₂₁N₃O₃ 
• 713145-44-9 C₂₁H₁₈F₃N₃O₃ 
• 773055-09-7 C₂₀H₁₈FN₃O₂ 
• 713145-67-6 C₂₀H₁₈ClN₃O₂ 
• 773848-96-7 C₂₁H₁₈N₄O₂ 
• 713145-47-2 1-(8-(3-methylsulfanyl-phenyl)-[1,7]naphthyridin-6-yl)-piperidine-4-carboxylic acid 
• 1295626-56-0 4-(8-ethyl-1,7-naphthyridin-6-yl)benzoic acid 

Relevant academic research and scientific papers

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate

The solubility-driven optimization of a series of 1,7-napthyridine phosphodiesterase-4 inhibitors is described. Directed structural changes resulted in increased aqueous solubility, enabling superior pharmacokinetic properties with retention of PDE4 inhib

Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4)

Figure Presented. A survey of PDE4 inhibitors reveals that some compounds trigger intracellular aggregation of PDE4A4 into accretion foci through association with the ubiquitin-binding scaffold protein p62 (SQSTM1). We show that this effect is driven by i

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: Discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives

The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3′-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives. In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound.

A scalable synthesis of a 1,7-naphthyridine derivative, a PDE-4 inhibitor

A six-step synthesis of a 4-[8-(3-fluorophenyl)[1,7]naphthyridin-6-yl]- trans-cyclohexanecarboxylic acid with an overall yield of 27% starting from 2-cyano-3-methylpyridine, cyclohexane-1,4-dicarboxylic acid dimethyl ester, and 3-fluorophenylboronic acid is described. The trans stereochemistry in the cyclohexane moiety was achieved through a series of equilibration steps at different stages of the synthesis.

INHIBITORS OF PI3 KINASE

The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1, X2, R1 and Z are as defined herein.

ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION

Compounds are provided which are useful for the treatment of serotonin-affected neurological disorders which comprise (I) wherein: Ra, R1, R2 and R3 are each, independently, hydrogen, or a substituent selected from halogen, CF3, alkyl, alkoxy, MeSO2, amino or aminocarbonyl (each optionally substituted by one or two groups selected from alkyl and benzyl) carboxy, or alkoxycarbonyl; or two adjacent of Ra and R1-4 together can form a 5-7 membered carbocyclic or heterocyclic ring which is optionally substituted by a substituent defined above; R4 is hydrogen, halogen, or alkyl; R5 is hydrogen, alkyl, arylalkyl, or aryl; R6 is hydrogen, halogen, CF3, CN, carbamide, alkoxy or benzyloxy; X1, X2 and X3 are each carbon or one of X1, X2 or X3 may be nitrogen; Y is CH or nitrogen; and Z is carbon or nitrogen; or pharmaceutically acceptable salts thereof.

Naphthyridine derivatives

PCT No. PCT/EP97/05898 Sec. 371 Date Apr. 27, 1999 Sec. 102(e) Date Apr. 27, 1999 PCT Filed Oct. 24, 1997 PCT Pub. No. WO98/18796 PCT Pub. Date May 7, 1998Novel 8-aryl-1,7-naphthyridines, in free or salt form, are PDE IV inhibitors and are thus useful as pharmaceuticals, e.g. for asthma therapy. Preferred compounds include compounds of formulae (I and II) wherein the R groups are as defined. Pharmaceutical compositions comprising the compounds, processes for preparation of the compounds and novel intermediates for use in the processes are disclosed.

Palladium-catalyzed cross-coupling reactions for the synthesis of 6,8- disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase type 4D inhibitors

Recently, four subtypes of the human phosphodiesterase type 4 (PDE4A-D) enzyme have been described. So far, only very few PDE4 subtype-selective inhibitors are known. Herein, we describe the synthesis of 6,8-disubstituted 1,7-naphthyridines and their characterization as potent and selective inhibitors of PDE4D which suppress the oxidative burst in human eosinophils with IC50 values as low as 0.7 nM. SAR development and the extended use of palladium-catalyzed cross-coupling reactions led to compound 11 which inhibited human PDE4D with an IC50 value of 1 nM. Thus, compound 11 was 55, 175, and 1000 times more potent in inhibiting PDE4D over PDE4B, PDE4A, and PDE4C. In a Brown Norway rat model of allergic asthma, compound 11 when given by the oral route (1 mg/kg) reduced by more than 50% the influx of eosinophils, T-cells, and neutrophils into bronchoalveolar lavage fluid (BALF) samples obtained from antigen-challenged animals. Thus, PDE4D- selective inhibitors of the 1,7-naphthyridine class have the potential as an oral therapy for treating asthma.